Molecular targets of pomegranate (*Punica granatum*) in preventing cancer metastasis

Naghmeh Ahmadiankia 1*

1Cancer Prevention Research Center, Shahroud University of Medical Sciences, Shahroud, Iran

**Abstract**

Metastasis is the primary cause of mortality and morbidity among cancer patients and accounts for about 90% of cancer deaths. The most common types of treatment for cancer metastasis are chemotherapy and radiotherapy. However, such therapy has many serious side effects that could diminish the quality of life in patients. There is increased appreciation by the scientific community that natural compounds can be potential weapons in fighting against cancer. Interestingly, much evidence shows that pomegranate (*Punica granatum*) has great potential to inhibit tumor growth and metastasis. In this review, we discussed the molecular targets of pomegranate, specifically those that are prerequisite for cancer metastasis. The search was performed in Google Scholar, Medline, Scopus, and PubMed using keywords such as metastasis, pomegranate, and signaling pathways. Some of the most important papers from the research results were included. Based on recent studies, some molecules, including those involved in cell-cell and cell-extracellular matrix adhesions, are affected by pomegranate. The other targets of pomegranate are modulators of cytoskeleton dynamics and regulators of cancer cell anoikis and chemotaxis. Furthermore, the antimetastatic effect of pomegranate may be attributed to molecular changes of the extracellular matrix. Pro-inflammatory and pro-angiogenic molecules are the other targets of pomegranate regarding cancer metastasis. A wide variety of molecules can be targeted by pomegranate to suppress tumor metastasis. A better understanding of the molecules regulated by pomegranate is needed to provide a rational basis for its clinical application.

**Introduction**

Cancer is a major public health problem and one of the leading causes of death worldwide (1). It is estimated that metastasis is responsible for about 90% of cancer deaths (2). Cancer metastasis is a multistep process by which tumor cells spread from the primary tumor site to distant organs through blood and lymphatic vessels. The first step in cell dissemination is detachment from the primary tumor. Epithelial and endothelial cells will undergo apoptosis when detached from the extracellular matrix (ECM), a phenomenon referred to as anoikis; however, cancer cells develop anoikis resistance that is a critical step in metastasis. Anoikis resistance cells leave the primary tumor site, intravasate, circulate in vessels, and finally extravasate from the circulation in the distant organ where they form a secondary new tumor (3). During multiple steps of metastasis, different molecules including those involved in cell–cell and cell–ECM adhesions, the modulators of cytoskeleton dynamics, the ones that organize ECM, and the signaling molecules involved in anoikis, chemotaxis, angiogenesis, and inflammatory responses are involved. Nowadays, chemotherapy as a conventional treatment is available for patients with cancer metastasis. However, the current chemotherapy agents fail to selectively and effectively kill cancer cells, and they usually have adverse side effects (4). Therefore, a safe, non-toxic, and highly effective regimen to fight cancer should be developed. Previous studies showed that consuming natural products is inversely associated with cancer incidence and mortality (5). Among them, pomegranate (*Punica granatum*) has been shown to inhibit the progression of cancer in different preclinical and clinical studies (6-8). It is an antioxidant-rich fruit containing different important bioactive compounds and alters many of the cellular and molecular processes involved in cancer progression (9). In this review article, we first discussed the phytochemical content of pomegranate and its chemotherapeutic properties. Then we explained studies on the molecular targets of pomegranate and its active constituents regarding cancer metastasis. Understanding the mechanism of pomegranate action and identification of its molecular targets provide a rational basis for its clinical application.

**Research method**

The current search was done in Google Scholar, Medline, Scopus, and PubMed through search words such as "anoikis, cell adhesion, chemotaxis, cytoskeleton dynamics, extracellular matrix, phytochemicals, metastasis, and pomegranate." The search was carried out to include literature published as late as 1 September 2018.
Phytochemical content of pomegranate

Pomegranate is one of the oldest known fruit tree species, native to central Asian regions spreading from Iran to northern India, the Mediterranean area, and the Middle East. It is valued for its nutritional, medicinal, ornamental, and industrial properties (10). The pomegranate plant is divided into several parts, including fruit (peel, juice, and seeds), leaves, flowers, roots, and bark. There is a wide range of phytochemicals in its different parts, which are summarized in Table 1.

Table 1. Different classes of phytochemicals identified in various parts of the pomegranate tree and fruit (11, 12)

| Classes | Phytochemicals (tissue source) |
|---------|-------------------------------|
| Ellagitannins, Gallotannins, and derivatives | Brevitol (Leaf), Brevitol carboxylic acid (Leaf, Flower, Heartwood), Brevitol carboxylic acid 10-monopotassium sulphate (Leaf), Castalagin (Stem bark), Cassarin (Stem bark), Casuarin (Peel, Stem bark), Corilagin (Peel, Leaf), Isocorilagin (Flower), Hippomanin A (Flower), Gemin D (Flower), Diellagic acid rhamnopyranosyl (4→8) glucopyranoside (Heartwood), 1,2-Di-O-galloyl-4,6-O-(S)-hexahydroxydiphenoyl β-D-glucopyranoside (Flower), Ellagic acid (Peel, Flower, Leaf), 3,3′-Di-O-methylated Ellagic acid (Seed), 3,3′,4′-Tri-O-methylated Ellagic acid (Seed), 3-O-Methylated Ellagic acid (Heartwood), 4,4′-Di-O-methylated Ellagic acid (Heartwood), 3,6-O-Methyleneoxy-ellagic acid (Heartwood), Eschweilolenol C (Ellagic acid 4-O-a-L-rhamnopyranoside) (Heartwood), Ethyl b-rhavlinocarboxylate (Flower), Esculcin (Arl), Escucarpin T1 (Arl), Pomegranate A (Arl), Pomegranate B (Arl), Gallagic acid (Peel), Gallic acid 3-O-β-D-(4-O-galloyl)-glucopyranoside (Flower), 6-O-Galloyl-2,3-(S)-hexahydroxydiphenoyl-D-glucose (Stem bark, Juice), 5-Galloyl-punicacrine (D, Heartwood), 2-O-Galloyl-4,6-(S,S)-gallagyl-D-glucose (Heartwood, Stem bark), Granatin A (Fruit, Leaf), Granatin B (Fruit, Leaf), 2,3-(S)-Hexahydroxydiphenoyl-D-glucose (Stem bark, Juice), Lagerstettin B (Peel), Lagerstettin C (Juice), 3-O-Methylation Ellagic acid 4-O-a-L-rhamnopyranoside (Heartwood), 3,4′-O-Dimethylated Ellagic acid 4-O-a-L-rhamnopyranoside (Heartwood), Oenothinin B (Arl), Pedunculagin I (Peel, Stem bark), Pedunculagin II (Juice), 1,2,3,4,6-Penta-O-galloyl-D-glucose (Leaf), 3,4,8,10-Pentahydroxydibenzo (b,d) pyran-6-one (Leaf), Phyllanthusiin E (Flower), Pomegranatol (Flower), Punicacoretic A (Stem bark), Punicacoretic B (Stem bark), Punicacoretic C (Stem bark, Peel), Punicacoretic D (Stem bark), Punicalcolin (Leaf), Punicalagin A (Peel, Stem bark, Aril, Juice, Root), Punicatin B (Peel, Stem bark, Aril, Juice, Root), Punicatin (Peel, Stem bark, Aril, Juice, Heartwood), Punicatinin A (Flower), Punicatinin B (Flower), Puniglucin (Stem bark), Strictinin (1-O-Galloyl-4,6-(S)-hexahydroxydiphenoyl-D-glucose) (Leaf), Tellimagrandin I (Peel), Terrcatanin (1,4-Di-O-galloyl-3,6-(R)-hexahydroxydiphenoyl-β-D-glucopyranoside) (Leaf), Terminalag (Galaglyl dilactone) (Stem bark), 1,2,4,6-Tetra-0-galloyl-β-D-glucose (Leaf), 1,2,3-Tri-O-galloyl-β-D-glucopyranose (Leaf), 1,2,4-Tri-O-galloyl-β-D-glucopyranose (Leaf), 1,2,6-Tri-O-galloyl-β-D-glucopyranose (Leaf), 1,3,4-Tri-O-galloyl-β-D-glucopyranose (Leaf), 1,4,6-Tri-O-galloyl-β-D-glucopyranose (Leaf), 3,4,6-Tri-O-galloyl-β-D-glucopyranose (Flower), Valonic acid dilactone (Juice, Peel) |

Flavonoids and anthocyanins

Hovretichicose C (Flower), Phlorizin (Juice), Phloretin (Flower), Eriodictyol-7-O-a-L-arabinofuranosyl (3→6)-β-D-glucoside (Stem bark), Granatum flavan yloside (Flower), Naringin (Naringenin-7-O-rhamnoglucoside) (Peel), Naringenin-4′-methyl ether 7-O-a-L-arabinofuranosyl (4→6)-β-D-glucoside (Stem bark), Pinoferitin (Juice), Punicalavanol (Flower), Apigenin (Peel), Apigenin 4′-O-β-glucopyranoside (Leaf), Luteolin (Peel, Flower), Luteolin 3′-O-β-glucopyranoside (Leaf), Luteolin 4′-O-β-glucopyranoside (Leaf), Cyanoside (Luteolin 7′-O-glucoside) (Peel), Luteolin 3′-O-β-sylxyloside (Leaf), Tricetin (Leaf), Daidzein (Seed), Genistein (Seed), Amurensin (Noricaritin 7′-O-glucopyranoside) (Juice), Kaempferol (Peel), Astragalin (Kaempferol 3′-O-glucoside) (Peel), Kaempferol-3′-O-rhamnoglucoside (Juice), Myricetin (Peel), Phellatin (Juice), Quercitin (Juice, Leaf, Seed, Peel), Hirsutin (Quercetin-3′-O-glucoside) (Peel), Quercetin-7′-O-glucoside (Peel), Quercetin 3′-O-rhamnoglucoside (Peel), Rutin (Quercetin-3′-O-rutinoside) (Juice), Quercetin-3,4′-dimethyl ether 7-O-a-L-arabinofuranosyl (4→3)-β-D-glucoside (Stem bark), Cyanidin (Juice), Chrysanthemin (Cyanidin-3′-O-glucoside) (Juice), Cyan (Cyanidin-3,5-di-O-glucoside) (Juice), Antirhizin (Cyanidin-3′-O-rutinoside) (Juice), Catechin-cyanidin-3-hexoside (Juice), Delphinidin (Juice), Myrtillin (Delphinidin-3′-O-glucoside) (Juice), Delphinidin-3,5-di-O-glucoside (Juice), Pelargonidin (Juice), Callistephin (Pelargonidin-3′-O-glucoside) (Juice), Pelargonin (Pelargonidin-3,5-di-O-glucoside) (Juice), Catechin (Peel, Juice, Leaf), Epicatechin (Peel, Juice, Leaf, Seed), Epicatechin gallate (Peel), Epigallocatechin-3′-O-gallate (Fruit), Gallocatechin (4→6)-catechin (Peel), Gallocesthin (4→6)-gallocatechin (Peel), Catechin (4→8)-gallocatechin (Peel), Procyanidin A2 (Peel), Procyanidin B1 (Peel), Procyanidin B2 (Peel), Procyanidin B3 (Peel) |

Lignans

Conidendrin (Juice), isohyboxymatairesinol (Peel), Isolaricetin (Juice, Peel), Matairesinol (Wood knot), Medioresinol (Juice, Wood knot, Seed), Phylligenin (Peel), Pinoreisol (Juice), Secoisolariciresinol (Peel, Juice), Syringaresinol (Juice, Wood knot, Seed), Pomegranalgin (Arl, Peel), Punicatinin C (Flower) |

Pharmacokinetics of pomegranate

The most abundant polyphenols in pomegranate juice are ellagitannins that are hydrolyzable tannins releasing ellagic acid on hydrolysis (13). The absorption of ellagitannins is rather low in humans (14). Interestingly, gut microbiota metabolizes ellagitannins and ellagic acid leading to the formation of urolithin A, urolithin B, and isourolithin A (15). The metabolites of urolithin A and urolithin B are conjugated in the liver, then excreted in urine (16). Due to difference in gut microbiota,
Continued Table 1

| Triterpenoids and phytosterols | Asiatic acid (Flower), Betulinic acid (Betulinic acid) (Leaf), Friedelooltan-3-one (Friedelin) (Stem and Root bark), Madinolic acid (Flower), Oleaerolic acid (Flower), Punicanolic acid (Flower, Peel), Ursolic acid (Flower, Campesterol (Seed), Cholesterol (Seed), Dauccosterol (Seed, Flower), 9S-Sitosterol (Seed, Flower), 9β-Sitosterol laurate (Peel), 9β-Sitosterol myristate (Peel), Stigmasterol (Seed) |

| Alkaloids and indolamines | N-(2′,5′-dihydroxyphenyl)pyrrolinium Chloride (Leaf), Hygrine (Root bark), Norhygrine (Root bark), Pelletierine (Stem and Root bark), N-methylpelletierine (Stem and Root bark), Norpreudopelletierine (Stem and Root bark), Pseudopelletierine (Stem and Root bark), 2-(2′-Hydroxypropyl)-d/piperidine (Root bark), 2-(2′-Propenyl)-d/piperidine (Root bark), Punigratane (2,5-Dihexyl-N-methyl pyrrolidine) (Peel), Sedridine (Root bark), Melatonin (Fruit extract), Serotonin (Fruit extract), Tryptamine (Fruit extract) |

| Fatty acids and lipids | Caproic acid (Hexanoic acid) (Juice), Caprylic acid (Octanoic acid) (Juice), Capric acid (Decanoic acid) (Juice), Lauric acid (Dodecanoeic acid) (Seed), Myristic acid (Tetradecanoic acid) (Seed, Fruit), Myristoleic acid (9-cis-Tetradecanoic acid) (Seed), Palmitic acid (Hexadecanoic acid) (Seed, Fruit), Palmitoleic acid (Hexadec-9-enoic acid) (Seed, Fruit), Punicic acid (9Z, 11E, 13Z-octadecatrienoic acid) (Seed), Linoleic acid (cis-9,12-Octadecadienoic acid) (Seed, Fruit), α-Linolenic acid (All-cis-9,12,15-octadecatrienoic acid) (Seed, Fruit), γ-Linolenic acid (All-cis-6,9,12-octadecatrienoic acid) (Seed, Fruit), Oleic acid (9Z-Octadecenoic acid) (Seed, Fruit), Stearic acid (Octadecanoic acid) (Seed, Fruit), α-Eleostearic acid (9Z, 11E, 13E-octadecatrienoic acid) (Seed), β-Eleostearic acid (9E, 11E, 13E-octadecatrienoic acid) (Seed), Catalpic acid (9E, 11E, 13Z-octadecatrienoic acid) (Seed), Arachidic acid (Eicosanoic acid) (Seed, Fruit), Gadoleic acid (9Z-Icosanoic acid) (Seed), Behenic acid (Docosanoic acid) (Seed), Nervonic acid (cis-15-Tetraicosanoic acid) (Seed, Fruit), 1-O,9-E,11Z,13E-Octadecatetrayl glycerol (Seed, Peel), 1-O-Isopentyl-3-O-lauratoyl glycerol (Seed, Fruit) |

| Organic acids and phenolic acids | Ascorbic acid (Leaf, Peel, Seed, Juice), Citric acid (Juice, Leaf, Peel, Seed), Fumaric acid (Juice), L-Malic acid (Juice, Leaf, Peel, Seed), Oxalic acid (Juice, Leaf, Peel, Seed), Quinic acid (Juice), Succinic acid (Juice, Leaf, Peel, Seed), Tartaric acid (Juice), Caffeic acid (Peel, Juice, Seed, Leaf), Chlorogenic acid (Juice, Cinnamic acid (Juice), e-Coumaric acid (Juice), p-Coumaric acid (Peel, Juice, Seed, Leaf), cis-p-Coumaric acid (Peel), Coutaric acid (Peel), 7,8-Dihydroxy-3-carboxymethylcoumarin-5-carboxylic acid (Flower), Ferulic acid (Juice, Seed, Peel, Leaf), Gallic acid (Peel, Juice, Flower), Methyl gallate (Heartwood), Neochlorogenic acid (5-O-Caffeoylquinic acid) (Peel, Juice), Protocatechuic acid (Peel, Juice), Vanillic acid (Peel, Juice), Coniferyl 9-O-[(6R,7R)-7,8-Dihydroxy-3-carboxymethylcoumarin-5-carboxylic acid] (Flower), Sinapic 9-O-[(6R,7R)-7,8-Dihydroxy-3-carboxymethylcoumarin-5-carboxylic acid] (Flower), Syringaldehyde (Juice) |

| Other compounds | Catechol (Juice), Coumestrol (Seed), Icariside D1 (Seed), Phenylethylfrutosinose (Seed), Syringaldehyde (Juice) |

Different urolithin metabotypes (UMs) including UMA, UM-B, and UM-0, are produced in some individuals (17). These urolithins circulate in the blood and reach many target organs where the effects of pomegranate ellagitannins are noted (18,19). Previous studies showed that the highest production of urolithin was carried out in distal parts of the intestine in humans and pigs (20, 21). Urolithin appears in plasma and urine at significant concentrations, around 24 hr after ellagic acid intake (14, 22). Mertens-Talcott et al. investigated the absorption of a standardized extract from pomegranate in healthy human volunteers after the acute consumption of 800 mg of extract. Results indicated that ellagic acid from the extract is bioavailable, with an observed C(max) of 33 ng/ml at t(max) of 1 hr. They also identified the metabolites of urolithin A, urolithin B, hydroxyl-urolithin A, urolithin A-glucoronide, and dimethyl ellagic acid-glucuronide in plasma (23). Moreover, Seeram et al. demonstrated that consuming 180 ml of pomegranate juice concentrate was associated with maximum plasma concentrations of ellagitannins of 0.06 mmol/lit after 1 hr and the ellagitannins metabolites, total urolithin A of 0.14 mmol/lit, and total urolithinB of 0.01 at 6 hr (24). They also detected ellagic acid in human plasma at a maximum concentration (31.9 ng/ml) after 1 hr post ingestion, which was rapidly eliminated within 4 hr (25).

In another study, 1-liter pomegranate juice was given orally to healthy volunteers for five days. The results showed that punicalagin and ellagic acid present in the juice were not detected either in plasma or in urine however three microbial ellagitannin-derived metabolites were detected in both urine and plasma with great interindividual variability one day after pomegranate juice consumption (18). Interestingly, under simulated gastrointestinal conditions, up to 80% of the overall ellagic acid content was slowly released from fermented pomegranate wastes over 2 hr incubation at the slightly alkaline pHs simulating the small intestine environment (26). It was revealed that ellagic acid had poor absorption and rapid elimination after oral administration of pomegranate leaf extract, and part of it was absorbed from the stomach (27). In another study, pomegranate seed oil was given to the animals intragastrically for 40 days at concentrations of 1%, 2%,...
and 4%. The results have demonstrated that punicic acid from pomegranate seed oil was metabolized and incorporated in the form of conjugated linoleic acid in different rat tissues (28). Further research is warranted to determine the pharmacokinetics of pomegranate.

**Clinical value of pomegranate**

Various chemical compounds in different parts of the pomegranate plant have crucial roles in the treatment of many diseases. For example, the rich phytochemical contents in seeds, leaves, and fruit have been attributed for their benefits in the treatment of diabetes (29, 30). Pomegranate extract has also shown protective effects against acute renal failure (31). Moreover, pomegranate seed has been reported to regulate urine discharge and control the burning sensation of urine (32). Punicalagin isolated from pomegranate peel exhibited anti-viral property against the herpes virus (33). Similarly, pomegranate polyphenol extract inhibits the influenza virus (34). Attenuation of atherosclerotic and lowered hypertension are the other clinical values of daily pomegranate juice intake (11). In traditional medicine, pomegranate peel extract could be beneficial in oxidative stress-induced degenerative diseases such as Alzheimer’s dementia (35). Additionally, the therapeutic role of peel and seed oil extract in preventing bone loss in preclinical models of osteoporosis has been proven (36, 37). Interestingly, pomegranate extract can accelerate the wound healing process in albino rats (38). Moreover, the beneficial effects of pomegranate peel have been proven in infertility treatment (39). Recently, a new flavone glucoside, together with ellagitannins and flavones extracted from flowers of pomegranate showed anti-obesity properties (40). Previous studies have revealed that pomegranate has anti-cancer effects as well. The most promising findings show that pomegranate extract impedes the progression of prostate cancer (41). Additional studies indicate that pomegranate may protect against bladder (42), breast (43), cervical (44), colon (45), leukemia (46), liver (47), lung (48), ovarian (49), pancreatic (50), and skin (51) cancers, as well.

In the next part, we bring together some of available in vitro and in vivo evidence relevant to the possible molecular targets of pomegranate with respect to cancer metastasis (Table 2 & Figure 1).

**Molecular targets modulated by pomegranate regarding metastasis**

**Cell adhesion molecules and their regulators as targets of pomegranate**

Adhesion (attachment) and de-adhesion (detachment) are prerequisites for cellular motility and cancer metastasis (68). A group of cell adhesion molecules (CAMs) are involved in connecting cell to cell and cell to ECM components (69). A brief description of CAMs and their regulators, which are affected by pomegranate, is presented below (Figure 2).

**Cadherins**

Cadherins are transmembrane glycoproteins that mediate homophilic cell–cell adhesion. They constitute the core structural component of adherence junctions. E-cadherin is a member of this superfamily that is found in epithelial cells. The catenin complex, including α-catenin, β-catenin, γ-catenin, and p120 catenin link the intracellular domain of E-cadherin to the cytoskeleton (69). Disruption of E-cadherin or its linker proteins is the hallmark of epithelial mesenchymal transition (EMT), which is the most important mechanism behind the initiation of cancer metastasis. During EMT the cellular expression of cell adhesion molecules decreases, resulting in the formation of spindle-shaped morphology. Loss cell–cell connection allows tumor cells to disseminate and eventually metastasize. Several transcription factors have been implicated in the regulation of EMT, including the Snail family zinc finger transcription factors (Snail1 and Snail2), the Twist family basic helix–loop–helix transcription factors (Twist1 and Twist2), and the zinc finger E-box binding homeobox proteins (ZEB1 and ZEB2). The genes encoding cadherins, claudins, integrins, mucins, occludin, and ZO1 are repressed via these transcription factors.
Table 2. Antimetastatic effects of pomegranate determined in in vitro and in vivo pre-clinical studies

| Cancer type | Studied Model | In vitro/in vivo/correlative | Extract/Phytochemical | Mechanism | Ref |
|-------------|---------------|------------------------------|-----------------------|-----------|-----|
| Bladder     | Y24           | In vitro                     | Extract (juice)       | Inactivated PTEN/PI3K/AKT/mTORC1 pathway via p21 protein up-regulation | (42) |
| Breast      | MDA-MB-231    | In vitro                     | Extract (peel)        | Decreased expression of β-catenin & EMT markers | (52) |
|             | MDA-MB-231    | In vitro                     | Extract (peel)        | Down-regulation of metastasis-related genes | (53) |
|             | MDA-MB-231, MCF-7 | In vitro                  | Extract (seed oil)    | Reduced secretion of inflammatory cytokines | (54) |
|             | MDA-MB-231, MCF-7 | In vitro                  | Juice or a combination of luteolin+ellagic acid+punicic acid | Reduced expression of pro-inflammatory cytokines/chemokines, adhesion molecules, cytoskeletal & ECM proteins, & EMT markers | (55) |
| Colon       | HT-29, AOM-induced ACF rats | In vitro, in vivo        | Juice                 | Targeting miR-126-regulated pathways which contribute anti-inflammatory & anti-angiogenic mechanisms | (45) |
|             | HT-29         | In vitro                     | Juice, Tannin, Punicalagin | Abolish TNFα-induced AKT activation resulting modulation of inflammatory cell signaling | (57) |
| Liver       | DENA-induced rat hepatocarcinoma | In vitro                | Emulsion              | Suppression of the inflammatory cascade through modulation of NF-κB signaling pathway | (47) |
| Lung        | A549, H1299, LL/2 | In vitro                  | Extract (leaves)      | Reduction of MMP-2 & MMP-9 expression | (48) |
|             | A549          | In vitro                     | Galactomannan (PSP001) isolated from the fruit rind | Down-regulation of VEGF & MMPs | (58) |
| Ovarian     | A2780, ES-2 in nude mice | In vitro, in vivo          | Fruit juice, Ellagic acid, Luteolin | Decreased expression of MMP2 & MMP9 | (49) |
|             | A2780         | In vitro                     | Punicalagin           | Suppression of MMPs activities | (59) |
| Prostate    | LNCaP, LAPC4, CL1, DU145, LAPC4 in SCID mice | In vitro, in vivo        | Extract              | NF-κB blockade | (60) |
|             | LNCaP, HUVEC, LAPC4 in SCID mice | In vitro, in vivo        | Extract              | Decreased expression of HIF-1α & VEGF | (61) |
|             | DU145, PC3, LNCaP | In vitro                  | Luteolin+Ellagic acid+ Punicic acid | Decreased expression of oncogenic miRNAs & inhibition of the CXCR4/SDF1α chemotaxis axis, changes in the expression of cell adhesion & cytoskeletal proteins | (62) |
|             | PC-3, PL510   | In vitro                     | Ellagic acid          | Decreased secretion of MMP-2, inhibited collagenase IV activity | (63) |
|             | DU145, PC3, TRAMP-C1 | In vitro                  | Extract (peel)       | Down-regulation of MMPs | (64) |
|             | PC3           | In vitro                     | Ellagic acid, Caffeic acid, Luteolin, Punicic acid | - | (65) |
|             | PC3           | In vitro                     | Extracts (peel, juice, seeds) | Decreased expression of PLA2 | (66) |
| Renal       | ACHN, SN12C   | In vitro                     | Extract (juice)       | Inhibition of NF-κB and JNK pathways, consequently inhibition of EMT phenotype | (67) |
|             | A375, R16F10 in C57BL/6 mice | In vitro, in vivo        | Galactomannan (PSP001) isolated from the fruit rind | Down-regulation of VEGF & MMPs | (58) |

CXCR4: C-C chemokine receptor type 4; ECM: Extracellular matrix; EMT: Epithelial mesenchymal transition; ERK: Extracellular signal-regulated kinase; HIF-1α: Hypoxia-inducible factor 1; JNK: Jun N-terminal kinases; MMP: Matrix metalloproteinase; miRNA: microRNA; mTOR: Mammalian target of rapamycin; NF-κB: Nuclear factor-κB; PLA2: Phospholipases A2; PTEN: Phosphate and tensin homolog; SCID: Severe combined immunodeficient; SDT 4: Stromal cell-derived factor 1; TNF-α: Tumor necrosis factor-α; VEGF: Vascular endothelial growth factor

Factors (70, 71).

In an attempt to unravel the anticancer properties of pomegranate, the effects of specific pomegranate juice components on the metastatic potential of prostate cancer cells were examined. They found that luteolin, ellagic acid, and punicic acid as important components of pomegranate juice significantly decreased invasion in prostate cancer cells partly through increasing the E-cadherin protein level. Moreover, affymetrix microarray and real-time PCR analysis revealed that ellagic acid, luteolin, and punicic acid decrease the expression of Twist (62). Twist is a transcriptional repressor of E-cadherin expression in breast cancer cells that suppresses E-cadherin through the E-box elements on its promoter (71).

Moreover, it was revealed that pomegranate up-regulates miR-200c and down-regulates the expression of ZEB1 (52, 62). The miRNA-200 family has been shown
Ahmadian Pomegranate in preventing cancer metastasis

Nexilin
MARCKS
Vimentin

Integrins are the key proteins responsible for cell-ECM adhesion. They link the cytoskeleton to ECM molecules providing required forces for cell migration. Cell-ECM adhesion also activate signaling pathways essential for cell motile function. Integrins consist of α and β subunits. The integrin subunits α3, α5, α6, αv, β1, and β3 are considered as biomarkers of metastasis (69). A study showed that consumption of pomegranate peel extract in a mice model of osteoporosis, significantly decreased the expression of integrin β3 (66). Considering previous studies, there is not enough investigation on the effect of pomegranate on the expression of integrins involved in cell-ECM interactions.

Endothelial CAM

Cell adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin), are known to modulate cell-endothelium interactions. They mediate initial adhesion of cancer cells to activated endothelium, their rolling, extravasation, and finally, the establishment of metastatic lesions (83). It was shown previously that pomegranate juice increased the expression of miR-126, leading to reduction of VCAM-1 expression in Azoxymethane treated rats (45). Several mRNAs such as VCAM-1 have a complementary sequence within their 3′-untranslated region for miR-126 (84).

Clearly, there is a lack of studies addressing the effects of pomegranate on the adhesion molecules in cancer cells.

Regulators of cytoskeleton dynamics as targets of pomegranate

The cytoskeleton is a highly dynamic network that controls the cellular structure and movement. In this part, the effects of pomegranate on the molecules involved in the modulation of cytoskeleton dynamics are discussed (Figure 3).

Interestingly, fascin, as a key regulator of cytoskeleton dynamics, is down-regulated by pomegranate (62). Fascin is an actin-crosslinking protein that is required for the formation of actin-based cellular protrusions. Functional studies showed that fascin expression is involved in cell locomotion of both normal and neoplastic cells (85). It was revealed that fascin-1 mRNA...
was up-regulated in accordance with miR-133b down-regulation (86). Interestingly, pomegranate up-regulates the expression of miR-133b, which is accompanied by fascin down-regulation (62).

Profilin 1 is another member of actin-binding proteins, which participates in dynamic turnover and reconstruction of the actin cytoskeleton (87). Interestingly, decreased migration of urinary bladder cancer cells treated with pomegranate juice coincided with increased expression of profilin 1 (42).

Anillin and nexilin are scaffold proteins implicated in the regulation of cytoskeleton structure and also cell migration (88, 89). Interestingly, the expression of anillin and nexilin were decreased following pomegranate treatment (62). Myristoylated alanine-rich protein kinase C substrate (MARCKS) is localized to the plasma membrane and is an actin filament crosslinking protein. Phosphorylation by protein kinase C (PKC) or binding to calcium-calmodulin inhibits its association with actin and with the plasma membrane, leading to cell migration or invasion. It has been revealed that exogenous overexpression of MARCKS remarkably promoted cell attachment (90, 91).

Moreover, recent studies using prostate cancer cells showed that miR-21 promotes cell invasion by directly targeting MARCKS (92). Interestingly, pomegranate decreased the expression of miR-21 and increased MARCKS in prostate cancer cells (41, 62). Reversely, pomegranate juice increased the expression of miR-205 (41). It has been shown that miR-205 suppresses cell invasion in prostate cancer by inhibiting PKCs and N-chimearin (CHN1) (93). N-chimearin induces the formation of the actin-based structures lamellipodia and filopodia (94).

Vimentin is a kind of intermediate filament and one of the core components of the cytoskeletal network. It induces changes in cell shape, motility, and adhesion during EMT (95). In early works, the expression of vimentin in cancer cells was shown to be associated with a high risk of metastasis and poor prognosis (96). Bagheri et al. demonstrated that the expression of vimentin decreased in MDA-MB-231 cells following treatment with pomegranate peel extract (53). Previous studies showed that increased expression of miR-122 was correlated with reduced expression of vimentin (74). Increased expression of miR-122 following cell treatment with pomegranate components (62) may be correlated with decreased expression of vimentin in prostate cancer cells.

Taken together these results provide additional evidence that the antimetastatic effect of pomegranate may at least in part be mediated via genes and proteins involved in cytoskeleton dynamics.

Molecules associated with anoikis resistance as targets of pomegranate

Cancer cells acquire anoikis resistance to survive after detachment from the primary sites and travel through the circulatory and lymphatic systems to disseminate throughout the body (97). Researchers showed that ellagic acid could induce anoikis in ovarian carcinoma cells via inducing caspase-3 mediated apoptosis by increasing the Bax/Bcl-2 ratio (98). Moreover, the expression of Cyclooxygenase-2 (COX-2) was suppressed by pomegranate polyphenols (99). COX-2 inhibits anoikis by activating various pathways in different cancer types (100, 101). More study is needed to determine if pomegranate truly inhibits anoikis resistance in cancer cells.

Regulators of cell chemotaxis as targets of pomegranate

Chemotaxis of tumor cells in the surrounding microenvironment is essential for cancer cell dissemination during tumor progression and metastasis (102). C-X-C chemokine receptor type 4 (CXCR4) and its ligand, stromal cell-derived factor 1 alpha (SDF1α) are known as important chemotactic proteins in cancer metastasis (103, 104).

The expression of CXCR4 and SDF1α were decreased after treatment with luteolin, ellagic acid, and punicic acid as the important components of pomegranate juice. They also inhibited prostate cancer cell migration toward SDF1α. Interestingly, luteolin, ellagic acid, and punicic acid together decrease the expression of Gα13P, PI3K, and p-AKT proteins involved in the signaling downstream of CXCR4 (105). Among different microRNAs, miR-1 suppresses the expression of CXCR4 and its ligand SDF1α. It was found that miR-1 was up-regulated by luteolin, ellagic acid, and punicic acid (62). Furthermore, pomegranate decreased the expression of hypoxia-inducible factor-1 (HIF-1) (61). HIF-1 has been found to be a critical transcription factor for the expression of CXCR4 in a variety of cells, including tumor cells (106, 107). More studies are necessary to better understand the effects of pomegranate on the regulators of cancer cells chemotaxis.

Structural molecules of ECM and their regulators as targets of pomegranate

Since ECM is the key component of the tumor microenvironment, we asked whether ECM components are affected by pomegranate. Based on previous studies, pomegranate can prevent metastasis by affecting structural components of ECM (Figure 4).

One of the major structural proteins in ECM is Fibronectin

Figure 4. Schematic description showing the structural molecules of the extracellular matrix (ECM) as targets of pomegranate. COX-2: Cyclooxygenase-2; HAMMR: Hyaluronic acid-mediated motility receptor/CD168; TIMPs: Matrix metalloproteinases; PLA2: phospholipase A2; TIMPs: Tissue inhibitors of metalloproteinases; TNC: Tenascin C.
collagen. There is mounting evidence of the role of collagen-dense ECM in promoting metastasis in different cancers (108, 109). Collagen-I increases protumorigenic signaling cascades such as focal adhesion kinase (FAK), src family kinases (SFKs), and extracellular regulated kinase (ERK)1/2 in tumor cells (110). It was demonstrated that type I collagen, secreted by stromal fibroblasts, may augment the aggressive characteristics of breast cancer cells through induction of matrix metalloproteinase (MMP)-9 (111). The main group of enzymes responsible for protein degradation in ECM is MMPs. The degradation of ECM by different members of the MMP family removes the physical barriers for tumor cells and reveals the hidden sites in the ECM, where various cell receptors can be bound to. The ability to degrade ECM is a critical requirement for tumor invasion (112). Previous studies showed that pomegranate or its ingredients such as ellagic acid, caffeic acid, luteolin, and quercetin decreased the expression of collagen 1 and/or MMP-1,-2,-9, and -13 (48, 49, 53, 55, 62-64, 113, 114). This evidence suggests that the anti-metastatic role of pomegranate might be attributed, at least in part, to the reduction of collagen 1 and MMPs production by cancer cells.

Moreover, the level of phospholipase A2 (PLA2) transcript was decreased by polyphenols of pomegranate fermented juice, peel, and seed oil (62). PLA2 is a cytosolic enzyme responsible for prostaglandin production. It was shown that inhibition of prostaglandin reduced the release of MMPs and inhibited invasion in prostate cancer cells (115). Additionally, the expression and activation of MMPs are directly correlated to the expression of COX-2 in tumor cells (116). Interestingly, polyphenols in pomegranate decreased the expression of COX-2 (117), which may lead to down-regulation of MMPs and inhibition of metastasis.

Tissue inhibitors of metalloproteinases (TIMPs) are inhibitors of active MMPs (118). Previous studies revealed that pomegranate extract or its constituents up-regulate the expression of TIMPs (58). In vitro experiments confirmed that overexpression of miR-335 inhibits MMP-9 and collagen 1 promoter activity and protein expression (119). Moreover, recent studies showed that miR-21 promotes invasion by targeting MMP regulators (120, 121). Interestingly, pomegranate increased the level of anti-invasive miR-335 and decreased the expression of miR-21, which may represent antimetastatic targets of pomegranate (62). The expression of fibronectin as one of the other components of ECM decreased in breast cancer cells treated with pomegranate peel extract (53).

Furthermore, hyaluronic acid (HA) is a nonsulfated glycosaminoglycan in ECM that regulates cell adhesion and migration. One of the HA receptors is hyaluronic acid-mediated motility receptor/CD168 (HAMMR), which is a nonintegral cell surface receptor (122). HA binding to HAMMR stimulates downstream signaling that activates RhoA-activated protein kinase and the MAPK/extracellular signal-regulated protein kinase (ERK) 1/2 pathway, which results in the expression of genes that are required for motility and invasion in various cancers (123, 124). The finding that pomegranate down-regulates HAMMR (62) suggests that the antimetastatic effect of pomegranate may be partially due to inhibiting the HA signaling pathway.

tenascin-C (TNC) is one of the other ECM glycoproteins that drives the progression of many types of human cancer (125). TNC is able to interact with several ECM proteins and many cell-surface receptors, which enables it to influence cell migration (126). There is evidence that miR-335 acts as a metastasis-suppressive miRNA in breast cancer by inhibiting type I collagen and TNC (127). Interestingly, pomegranate increased the expression of miR-335 and inhibited the expression of collagen I and TNC (62).

**Inflammatory and angiogenic molecules as targets of pomegranate**

It has been increasingly recognized that inflammatory components fire up cancer metastasis. Interestingly, the expression of some inflammatory chemokines was decreased with treatment of pomegranate seed oil in breast cancer cells (54). Moreover, pomegranate juice significantly reduced the level of secreted IL-6, IL-12p40, IL-1β, and RANTES (regulated on activation, normal T Cell expressed and secreted) in prostate cancer cells (128). Previous studies showed that overexpression of these inflammatory cytokines confers migratory and invasive properties to many tumor cell lines (129). Moreover, pomegranate extract suppressed the expression of critical mediators of inflammation markers, including those of inducible nitric oxide (iNOS), COX-2, prostaglandin E2 (PEG-2), and HSP90 (99, 130).

Pomegranate extract has been found to down-regulate the expression of angiogenic factors such as vascular endothelial growth factor (VEGF). Moreover, previous studies showed that pomegranate seed oil and fermented pomegranate juice inhibited the expression of VEGF and increased expression of migration inhibitory factor (MIF) in breast cancer cells (56). It has been shown that pomegranate extract minimizes angiogenesis, tumor size, and metastasis by reducing the expression of VEGF (61).

**Perspective and limitation**

The overall purpose of this review is to briefly discuss the molecular targets of pomegranate with respect to cancer metastasis. Previous studies on pomegranate were mostly focused on fruit peel and juice. The antimetastatic activity of other tissues of pomegranate such as leaves, flower, seed, heartwood, and root should be studied in more detail. Moreover, as yet the antimetastatic effect of only a limited number of phytochemicals in pomegranate has been studied. Further in vitro assays and animal model studies should be performed to unravel the effects of other phytochemicals of pomegranate on the process of metastasis. Many phytochemicals in pomegranate are similar to other medicinal plants, so identification of underlying effect mechanisms of pomegranate will also promote our knowledge of molecular targets of other functional food plants.

Additionally, more comprehensive studies should be performed on the expression changes of metastasis related molecules following pomegranate use. A better understanding of the molecules regulated by pomegranate will undoubtedly enable its better clinical application.
Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2. Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog 2013;18:43-73.
3. Naderi-Meshkin H, Ahmadiania N. Cancer metastasis versus stem cell homing: Role of platelets. J Cell Physiol 2018;233:9167-9178.
4. Pearce A, Haas M, Viney R, Pearson SA, Brown C, et al. Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. PLoS One 2012;7:e0184360.
5. Kurnumakara AB. Anticancer properties of fruits and vegetables: A scientific review. World Scientific 2014.
6. Faller CJ, Ye XM, Wemikap KJ, Gillespie BK, Sieber PR, Grengold RH, et al. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis 2013;16:50-55.
7. Shanmugam MK, Lee JH, Chai EZ, Kanchi MM, Kar S, Arusofo F, et al. Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds. Semin Cancer Biol 2016;40:41-35-47.
8. Nunez-Sanchez MA, Gonzalez-Sarrias A, Garcia-Villalba R, Monedero-Saiz T, Garcia-Talavera NV, Gomez-Sanchez MB, et al. Gene expression changes in colon tissues from colorectal cancer patients following the intake of an ellagitannin-containing pomegranate extract: A randomized clinical trial. J Nutr Biochem 2017;42:126-133.
9. Syed DN, Chamcheu JC, Adhami VM, Mukhtar H. Pomegranate extracts and cancer prevention: molecular and cellular activities. Anticancer Agents Med Chem 2013;13:1149-1161.
10. Holland D, Hatib K, Bar-Yaakov I. Pomegranate: Botany, horticulture, breeding horticultural reviews, Vol. 35, Edited by JulesJanick Copyright & John Wiley & Sons inc 2009.
11. Wang D, Ozen C, Abu-Reiah IM, Chigurupati S, Patra JK, Horbanczuk JO, et al. Vasculoprotective effects of pomegranate (Punica granatum L.). Front Pharmacol 2018;9:554-559.
12. Wu S. Tea L. Diverse phytochemicals and bioactivities in the ancient fruit and modern functional food pomegranate (Punica granatum). Molecules 2017;22:pii:E1606.
13. Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 2000;48:4581-4589.
14. González-Sarrias A, Garcia-Villalba R, Núñez-Sánchez MA, Tomé-Carneiro J, Zafiri P, Mulerio J, et al. Identifying the limits for ellagic acid bioavailability: a crossover pharmacokinetic study in healthy volunteers after consumption of pomegranate extracts. J Func Foods 2015;19:225-235.
15. Tomas-Barberan FA, Gonzalez-Sarrias A, Garcia-Villalba R, Nunez-Sanchez MA, Selma MV, Garcia-Conesa MT, et al. Urolithins, the rescue of "old" metabolites to understand a "new" concept: Metabolotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status. Mol Nutr Food Res 2017;61.
16. Heber D. Pomegranate ellagitannins. 2011.
17. Tomas-Barberan FA, Garcia-Villalba R, Gonzalez-Sarrias A, Selma MV, Espin JC. Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status. J Agric Food Chem 2014;62:6535-6538.
18. Cerdá B, Espin JC, Parra S, Martinez P, Tomás-Barberán FA. The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy−6H−dibenzopyran−6−one derivatives by the colonic microflom of healthy humans. Eur J Nutr 2004;43:205−220.
19. Cerdá B, Soto C, Albaladejo M, Martinez P, Sanchez-Gascon F, Tomás-Barberan F, et al. Pomegranate juice supplementation in chronic obstructive pulmonary disease: a 5-week randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr 2006;60:245-253.
20. Garcia-Villalba R, Vissenaekens H, Pitart J, Romo-Vaquero M, Espin JC, Grootaert C, et al. Gastrointestinal simulation model TWIN-SHIME shows differences between human urolithin-metabotypes in gut microbiota composition, pomegranate polyphenol metabolism, and transport along the intestinal tract. J Agric Food Chem 2017;65:5480-5493.
21. Espin JC, Gonzalez-Barrio R, Cerda B, Lopez-Bote C, Rey AI, Tomas-Barberan FA. Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. J Agric Food Chem 2007;55:10476-10485.
22. Cerda B, Tomas-Barberan FA, Espin JC. Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: identification of biomarkers and individual variability. J Agric Food Chem 2005;53:227-235.
23. Mertens-Talcott SU, Jilma-Stohlawetz P, Rios J, Hingorani L, Derendorf H. Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum L.) polyphenols after ingestion of a standardized extract in healthy human volunteers. J Agric Food Chem 2006;54:8956-8961.
24. Seeram NP, Henning SM, Zhang Y, Suchard M, Li Z, Heber D. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 2006;136:2481-2485.
25. Seeram NP, Lee R, Heber D. Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta 2004;348:63-68.
26. Verotta L, Panzella L, Antenucci S, Calvenzani V, Tomay F, Petroni K, et al. Fermented pomegranate wastes as sustainable source of ellagic acid: Antioxidant properties, anti-inflammatory action, and controlled release under simulated digestion conditions. Food Chem 2018;246:129-136.
27. Lei F, Xing DM, Xiang L, Zhao YN, Wang W, Zhang LJ, et al. Pharmacokinetic study of ellagic acid in rat after oral administration of pomegranate leaf extract. J Chromatogr B Analyt Technol Biomed Life Sci 2003;796:189-194.
28. Pereira de Melo IL, de Oliveira ESAM, Yoshime LT, Gasparotto Settler JA, Teixeira de Carvalho EB, Mancini-Filho J. Punicic acid was metabolised and incorporated in the form of conjugated linoleic acid in different rat tissues. Int J Food Sci Nutr 2018;1:11.
29. Salwe KJ, Sachdev DO, Bahurupi Y, Kumarappan M. Evaluation of antidiabetic, hypolipidemic and antioxidant activity of hydroalcoholic extract of leaves and fruit peel of Punica granatum in male Wistar albino rats. J Nutr Sci Biol Med 2015;6:56-62.
30. Khajebishak Y, Payahoo L, Alvand M, Alipour B. Punicic Acid: A potential compound of pomegranate seed oil in Type 2 diabetes mellitus management. J Cell Physiol 2019;234:2112-2120.
31. Boozari M, Hosseinzadeh H. Natural medicines for acute renal failure: A review. Phytother Res 2017;31:1824-1835.
32. Rathod NR, Biswas D, Chitme HR, Ratna S, Muchandi IS, Chitraji VS, et al. The potential of pomegranate as a sustainable source of ellagic acid: Antioxidant properties, anti-inflammatory, and controlled release under simulated digestion conditions. Food Chem 2018;246:129-136.
33. Arunkumar J, Rajarajan S. Study on antiviral activities, drug-likeness and molecular docking of bioactive compounds
of *Punica granatum* L. to Herpes simplex virus - 2 (HSV-2). Microb Pathog 2018;118:301-309.
34. Haidari M, Ali M, Ward Casselle S, 3rd, Madjid M. Pomegranate (*Punica granatum*) purified polyphenol extract inhibits influenza virus and has a synergistic effect with oseltamivir. Phytomedicine 2009;16:1127-1136.
35. Yuan T, Ma H, Liu W, Niesen DB, Shah N, Crews R. Oseltamivir inhibits influenza virus and has a synergistic effect with *Pomegranate* (*Punica granatum*) pure chemicals show possible synergistic effects with *Punica granatum* leaves extract induces apoptosis through mitochondrial intrinsic pathway and inhibits metastasis in prostate cancer cells. Biomed Pharmacother 2018;105:227-235.
36. Liu H, Zeng Z, Wang S, Li T, Mantriani E, Li QH, et al. Main components of pomegranate, ellagic acid and luteolin, inhibit metastasis of ovarian cancer by down-regulating MMP2 and MMP9. Cancer Biol Ther 2017;18:990-999.
37. Nair V, Dai Z, Khan M, Ciolino HP. Pomegranate extract induces cell cycle arrest and alters cellular phenotype of human pancreatic cancer cells. Anticancer Res 2011;31:2699-2704.
38. George J, Singh M, Srivastava AK, Bhui K, Shukla Y. Synergistic growth inhibition of mouse skin tumors by pomegranate fruit extract and diallyl sulfide: evidence for inhibition of activated MAPKs/NF-kappaB and reduced cell proliferation. Food Chem Toxicol 2011;49:1511-1520.
39. Bagheri M, Fazli M, Saeednia S, Kor A, Ahmadiankia N. Pomegranate peel extract inhibits expression of beta-catenin, epithelial mesenchymal transition, and metastasis in triple negative breast cancer cells. Cell Mol Biol (Noisy-le-grand) 2018;64:86-91.
40. Ahmadiankia, N, Talaat IM, Elrashidy FH, Hegazy AY, Sultan AS. Therapeutic role of *Punica granatum* in preventing cancer metastasis. Iran J Basic Med Sci, Vol. 22, No. 9, Sep 2019
65. Lansky EP, Jiang W, Mo H, Bravo L, Froom P, Yu W, et al. Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Invest New Drugs 2005;23:11-20.

66. An J, Guo Y, Wang T, Puntack AJ, Rettig MB. Pomegranate extract inhibits EMT in clear cell renal cell carcinoma in a NF-kappaB and JNK dependent manner. Asian J Urol 2015;2:38-45.

67. Wells A, Omhovar J, Wheeler S, Ma B, Lauffenburger D. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci 2011;33:4:283-289.

68. Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B 2015;5:402-418.

69. TechaSuek, LoiLome W, Namwat N, Khuntkeo N, Puapairoj A, JearanaiKoon P, et al. Loss of E-cadherin promotes migration and invasion of cholangiocarcinoma cells and serves as a potential marker of metastasis. Tumour Biol 2014;35:8645-8652.

70. Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor formation. Mol Oncol 2011;7:28-39.

71. Guo F, Parker Kerrigan BC, Yang D, Hu L, Shmulevich I, Sood AK, et al. Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions. J Hematol Oncol 2014;7:19.

72. Song Y, Li J, Zhu Y, Dai Y, Zeng T, Liu L, et al. MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma. Oncotarget 2014;5:11669-11680.

73. Wang SC, Lin XL, Li J, Zhang TT, Wang HY, Shi JW, et al. MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA. PLoS One 2014;9:e101330.

74. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Colecchia M, et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase C-dependent pathway. Cancer Sci 2010;101:656-665.

75. Hafeez BB, Zheng W, Weichert J, Druschk-Schmidt NE, Jamal MS, Verma AK. Genetic ablation of PCK epson inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Cancer Res 2011;71:2318-2327.

76. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009;1:a001651.

77. Huber MA, Azotei N, Baumann B, Grunert S, Sommer A, Pehamberger H, et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. Clin Invest 2004;114:569-581.

78. Fires BR, Menalha AL, Ferrein GM, de Souza WF, Morgado-Diaz JA, Maia AM, et al. NF-kappaB is involved in the regulation of EMT genes in breast cancer. PLoS One 2017;12:e0169622.

79. Kumar M, Allison DF, Baranova NN, Wamsley JJ, Katz AJ, Bekiranov S, et al. NF-kappaB regulates mesenchymal transition for the induction of non-small cell lung cancer initiating cells. PLoS One 2013;8:e68597.

80. Nicolson GL, Veljkovic V, Glisic S, Perovic V, Veljkovic N. Pomegranate (Punica granatum): A natural source for the development of therapeutic compositions of food supplements with anticancer activities based on electron acceptor molecular characteristics. Functional Foods in Health and Disease 2016;6:769-787.

81. Martin TA. The role of tight junctions in cancer metastasis. Semin Cell Dev Biol 2014;36:224-231.

82. Salvador E, Burek M, Forster CY. Tight junctions and the tumor microenvironment. Curr Pathobiol Rep 2016;4:135-145.

83. Skubitz AP. Adhesion molecules. Cancer Treat Res 2002;107:305-329.

84. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A 2008;105:1516-1521.

85. Rodrigues PC, Sawazaki-Calone I, Ervolino de Oliveira C, Soares Macedo CC, Dourado MR, Cervigne NK, et al. Fascin promotes migration and invasion and is a prognostic marker for oral squamous cell carcinoma. Oncotarget 2017;8:74736-74754.

86. Hafeez BB, Zheng W, Weichert J, Druschk-Schmidt NE, Jamal MS, Verma AK. Genetic ablation of PCK epson inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Cancer Res 2011;71:2318-2327.

87. Li T, Li D, Sha J, Sun P, Huang Y. MicroRNA-21 directly targets MRCK and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 2009;383:280-285.

88. Goeppinger S, Follini M, Longoni N, Pennati M, Binda M, Colecchia M, et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase C-dependent pathway. Cancer Sci 2010;101:656-665.

89. Kozma R, Ahmed S, Best A, Lim L. The GTPase-activating protein n-chimaerin cooperates with Rac1 and Cdc42Hs to induce the formation of lamellipodia and filopodia. Mol Cell Biol 1996;16:5069-5080.

90. Kim YN, Koo KH, Sung JY, Yun UJ, Kim H. Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol 2010;2010:306879.

91. Chung YC, Lu LC, Tsai MH, Chen YJ, Chen YY, Yao SP, et al. Anti-inflammatory effect of ellagic Acid on cell growth of ovarian carcinoma cells. Evid Based Complement Alternat Med 2012;2012:306879.

92. Du L, Li J, Lei L, He H, Chen E, Dong J, et al. High vimentin expression predicts a poor prognosis and progression in colorectal cancer: A study with meta-analysis and TCGA database. Biomed Res Int 2018;2018:6307810.

93. Kim YN, Koo KH, Sung JY, Yun UJ, Kim H. Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol 2012;2012:306879.

94. Chung YC, Lu LC, Tsai MH, Chen YJ, Chen YY, Yao SP, et al. The inhibitory effect of ellagic Acid on cell growth of ovarian carcinoma cells. Evid Based Complement Alternat Med 2013;2013:306705.

95. Mandal A, Bhatia D, Bishayee A. Anti-inflammatory mechanism involved in pomegranate-mediated prevention of breast cancer: the role of NF-kappaB and Nrf2 signaling pathways. Nutrients 2017;9.

96. Chai EM, Kwak SJ, Kim YM, Ha KS, Kim JJ, Lee SW, et al. COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells. Exp Mol Med 2005;37:199-203.

97. Feng H, Li Y, Wang Y, Zhao H, Zhang J, Chai H, et al. NF-kappaB regulates mesenchymal transition and suppresses AKT activation in breast cancer cells. J Cell Physiol 2009;218:436-443.

98. Duan L, Li J, Lei L, He H, Chen E, Dong J, et al. High vimentin expression predicts a poor prognosis and progression in colorectal cancer: A study with meta-analysis and TCGA database. Biomed Res Int 2018;2018:6307810.

99. Mandal A, Bhatia D, Bishayee A. Anti-inflammatory mechanism involved in pomegranate-mediated prevention of breast cancer: the role of NF-kappaB and Nrf2 signaling pathways. Nutrients 2017;9.
Ahmadiankia Pomegranate in preventing cancer metastasis

102. Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer 2011;11:573-587.

103. Mishan MA, Ahmadiankia N, Bahrami AR. CXCR4 and CCR7: Two eligible targets in targeted therapy. Cell Biol Int 2016;40:955-967.

104. Ahmadiankia N, Moghaddam HK, Mishan MA, Bahrami AR, Naderi-Meshkin H, Bildkhori HR, et al. Berberine suppresses migration of MCF-7 breast cancer cells through down-regulation of chemokine receptors. Iran J Basic Med Sci 2016;19:125-131.

105. Wang L, Li W, Lin M, Garda M, Mulholland D, Lilly M, et al. Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis. Carcinogenesis 2014;35:2321-2330.

106. Guo M, Cai Z, Zhao G, Qiu X, Zha H, Ma Q, et al. Hypoxia promotes migration and induces CXCR4 expression via HIF-1alpha activation in human osteosarcoma. PLoS One 2014;9:e90518.

107. Zaggag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006;86:1221-1232.

108. Liu J, Sh en JX, Wu HT Li XL, Wen XF, Du CW, et al. Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target. Discov Med 2018;25:211-223.

109. Shintani Y, Hollingsworth MA, Wheeler MJ, Johnson KR. Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res 2006;66:11745-11753.

110. Provenzano PP, Inman DR, Eliceiri KW, Keely PJ. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. Oncogene 2009;28:5369-5380.

111. Kim SH, Lee HY, Jung SP, Kim S, Lee JE, Nam SJ, et al. The hyaluronan-mediated motility receptor RHAMM promotes growth, invasiveness and dissemination of colorectal cancer. Oncotarget 2017;8:70617-70629.

112. Mele V, Sokol L, Kolzer VH, Pfaff D, Muraro MG, Keller I, et al. The hyaluronan-mediated motility receptor RHAMM promotes growth, invasiveness and dissemination of colorectal cancer. Oncotarget 2017;8:70617-70629.

113. Paron I, Berchtold S, Voros J, Shamarla M, Erkan M, Hofler H, et al. The role of tenascin-C in tissue remodeling and motility and affects cell adhesion through activation of the integrin pathway. PLoS One 2011;6:e21684.

114. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linley PS, et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 2009;29:6987-6997.

115. Mele V, Sokol L, Kolzer VH, Pfaff D, Muraro MG, Keller I, et al. The hyaluronan-mediated motility receptor RHAMM promotes growth, invasiveness and dissemination of colorectal cancer. Oncotarget 2017;8:70617-70629.

116. Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer 2011;11:573-587.

117. Mishan MA, Ahmadiankia N, Bahrami AR. CXCR4 and CCR7: Two eligible targets in targeted therapy. Cell Biol Int 2016;40:955-967.

118. Bourboulia D, Stellen-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010;20:161-168.

119. Wang W, Yang C, Wang X, Zhou L, Lao GJ, Liu D, et al. MicroRNA-129 and -335 promote diabetic wound healing by inhibiting Sp1-Mediated MMP-9 expression. Diabetes 2018;67:1627-1638.

120. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009;82:21-29.

121. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linley PS, et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 2009;29:6987-6997.

122. Mele V, Sokol L, Kolzer VH, Pfaff D, Muraro MG, Keller I, et al. The hyaluronan-mediated motility receptor RHAMM promotes growth, invasiveness and dissemination of colorectal cancer. Oncotarget 2017;8:70617-70629.

123. Tavazoie SF, Alarcon C, Oskarsson T, Pa du a D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008;451:147-152.

124. Wang L, Alon A, Yuan H, Ho J, Li QJ, Martiniz-Green M. Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Integr Biol (Camb) 2011;3:742-754.

125. Wang L, Alon A, Yuan H, Ho J, Li QJ, Martiniz-Green M. Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Integr Biol (Camb) 2011;3:742-754.

126. Wang L, Alon A, Yuan H, Ho J, Li QJ, Martiniz-Green M. Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Integr Biol (Camb) 2011;3:742-754.

127. Wang L, Alon A, Yuan H, Ho J, Li QJ, Martiniz-Green M. Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Integr Biol (Camb) 2011;3:742-754.

128. Wang L, Alon A, Yuan H, Ho J, Li QJ, Martiniz-Green M. Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Integr Biol (Camb) 2011;3:742-754.

129. Wang L, Alon A, Yuan H, Ho J, Li QJ, Martiniz-Green M. Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Integr Biol (Camb) 2011;3:742-754.

130. Wang L, Alon A, Yuan H, Ho J, Li QJ, Martiniz-Green M. Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Integr Biol (Camb) 2011;3:742-754.